Compare MCB & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCB | FBRX |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 899.4M |
| IPO Year | 2017 | 2017 |
| Metric | MCB | FBRX |
|---|---|---|
| Price | $98.48 | $48.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $98.67 | $67.00 |
| AVG Volume (30 Days) | 137.7K | ★ 824.3K |
| Earning Date | 04-21-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | 11.64 | ★ 61.30 |
| EPS | ★ 2.92 | N/A |
| Revenue | ★ $11,053,000.00 | $36,000.00 |
| Revenue This Year | $37.22 | N/A |
| Revenue Next Year | $14.75 | N/A |
| P/E Ratio | $34.60 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $64.66 | $9.25 |
| 52 Week High | $102.04 | $46.33 |
| Indicator | MCB | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 86.78 |
| Support Level | $86.38 | $24.72 |
| Resistance Level | $102.04 | N/A |
| Average True Range (ATR) | 2.49 | 4.54 |
| MACD | -0.16 | 2.73 |
| Stochastic Oscillator | 49.34 | 97.62 |
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.